314 Stock Overview
Operates as a medical technology and health management company in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 314 from our risk checks.
Sipai Health Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.86 |
| 52 Week High | HK$35.95 |
| 52 Week Low | HK$4.89 |
| Beta | 0 |
| 1 Month Change | -0.68% |
| 3 Month Change | -11.21% |
| 1 Year Change | -80.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.56% |
Recent News & Updates
Shareholder Returns
| 314 | HK Consumer Retailing | HK Market | |
|---|---|---|---|
| 7D | -3.0% | -3.5% | 1.4% |
| 1Y | -80.7% | -42.6% | 3.2% |
Return vs Industry: 314 underperformed the Hong Kong Consumer Retailing industry which returned -42.6% over the past year.
Return vs Market: 314 underperformed the Hong Kong Market which returned 3.2% over the past year.
Price Volatility
| 314 volatility | |
|---|---|
| 314 Average Weekly Movement | 5.8% |
| Consumer Retailing Industry Average Movement | 8.1% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 15.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 314's share price has been volatile over the past 3 months.
Volatility Over Time: 314's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 3,089 | Xuguang Ma | www.medbankshealthtech.com |
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People’s Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty Pharmacy Business segment operates specialty pharmacy stores; and distributes pharmaceutical products to pharmaceutical companies and other distributors.
Sipai Health Technology Co., Ltd. Fundamentals Summary
| 314 fundamental statistics | |
|---|---|
| Market cap | HK$4.47b |
| Earnings (TTM) | -HK$275.83m |
| Revenue (TTM) | HK$5.08b |
0.9x
P/S Ratio-16.2x
P/E RatioIs 314 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 314 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.71b |
| Cost of Revenue | CN¥4.30b |
| Gross Profit | CN¥412.45m |
| Other Expenses | CN¥668.22m |
| Earnings | -CN¥255.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 8.75% |
| Net Profit Margin | -5.43% |
| Debt/Equity Ratio | 0.1% |
How did 314 perform over the long term?
See historical performance and comparison